A Case of Mania following Deep Brain Stimulation for Obsessive Compulsive Disorder


Introduction

Deep brain stimulation (DBS) of the basal ganglia is an effective treatment for select movement disorders, including Parkinson’s disease, essential tremor and dystonia. Based on these initial successes, DBS has been explored as an experimental treatment for medication-resistant neuropsychiatric disease. During a multiyear experience employing DBS to treat patients for obsessive compulsive disorder (OCD) we encountered several unanticipated stimulation-induced psychiatric side effects. We present a case of a young woman treated for OCD with DBS of the anterior limb of the internal capsule and nucleus accumbens region, who subsequently manifested a manic episode. We aim to discuss the case details, treatment and potential neuroanatomical underpinnings of this response.
We recently implanted DBS leads in 6 patients to treat medication-resistant OCD. The tip of the DBS lead was targeted to pass along the ALIC and approximately through the anterior commissure with the ventral extent to be placed within the NA. The target coordinates were (x, y, z) = (±6.0, 12.5, –5.0), where x = lateral, y = anteroposterior, and z = axial. Adapted from Haq et al. [31].

Fig. 1. Lead trajectory and contact coordinates for patient 6 based on postoperative CT to preoperative T1-weighted MRI fusion in right coronal (A), left coronal (B), right sagittal (C) and left sagittal (D) views. We employed a 3387-IES Medtronic DBS lead (3-mm-long contacts, 4-mm spacing). The tip of the electrode was targeted to pass along the ALIC and approximately through the anterior commissure with the ventral extent to be placed within the NA. The target coordinates were (x, y, z) = (±6.0, 12.5, –5.0), where x = lateral, y = anteroposterior and z = axial. Adapted from Haq et al. [31].

### Case Details

The study was approved by the institutional review board and the patients gave written informed consent before entering. To be eligible, the patients were required to have undergone adequate therapeutic trials of at least 3 classes of medication and also to have received multiple trials of cognitive behavioral therapy without benefit.

A 29-year-old woman with a history of severe OCD enrolled in the study. She reported that her OCD symptoms had manifested themselves at the age of 5 with obsessions that centered on a need to be clean and a need to please. At the time of enrollment, her compulsions included counting, bra-snapping, pant-pulling, and leg scratching. She completed the 12th grade but subsequently had difficulty remaining employed because of her illness. In addition to her history of OCD, she was also diagnosed as having major depressive disorder. Twice, in the remote past, she had attempted suicide via drug overdose. The patient underwent DBS and pulse generator implantation without ill effects. Details of the neurosurgical procedure have been previously published [12]. She had been randomized to the ‘activation at 30 days postoperative-

## Table

<table>
<thead>
<tr>
<th>Side</th>
<th>Contact 0</th>
<th>Contact 1</th>
<th>Contact 2</th>
<th>Contact 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x  y  z</td>
<td>x  y  z</td>
<td>x  y  z</td>
<td>x  y  z</td>
</tr>
<tr>
<td><strong>Right</strong></td>
<td>6.2/13.7/–4.1</td>
<td>9.4/16.3/2.4</td>
<td>12.5/18.9/8.9</td>
<td>15.7/21.5/15.4</td>
</tr>
<tr>
<td><strong>Left</strong></td>
<td>–8.2/12.6/–4.6</td>
<td>–11.2/15.6/1.7</td>
<td>–14.3/18.6/8.0</td>
<td>–17.4/21.5/14.4</td>
</tr>
</tbody>
</table>
ly’ group, and 1 month after implantation her generators were turned on.

Following a detailed screening procedure, in which we assessed patient response to stimulation settings in a blinded manner [12], the subject was set to what were felt to be the clinically optimal contact and parameter settings (table 1). Though electrode placement within the ALIC-NA was chosen in order to facilitate stimulation at either the ALIC or NA, our experience with the previous 5 patients in this trial [12], as well as the experience of other centers [20], led us to attempt stimulation of the NA first. Within 30 min after device activation, the patient’s speech became rapid and pressured. Our initial concern was lead misplacement or migration. A CT scan of her head confirmed accurate lead position without intracranial hemorrhage or lead migration. During this procedure the patient continued to be unusually ebullient and talkative. She repeatedly interrupted the scan in order to express her gratitude, rising from the scanner several times in order to thank and hug the staff. She was noticed to be unusually upbeat and voluble. This behavior was in marked contrast to her usually restricted affect and quiet demeanor. She was subsequently admitted to the psychiatric ward for inpatient observation.

Her medication regimen at the time of admission consisted of fluoxetine (100 mg daily), lamotrigine (200 mg q.h.s.), eszopiclone (3 mg q.h.s.), pregabaline (50 mg b.i.d.), clonazepam (1 mg daily) and topiramate (25 mg q.h.s.). Her DBS programming parameters at this time were (bilaterally) 1–C+ with a PW of 210 µs, frequency of 135 Hz and voltage of stimulation of 4.8.

**Table 1. Programming settings and patient behaviors**

<table>
<thead>
<tr>
<th>Days after activation</th>
<th>Time</th>
<th>Right settings</th>
<th>voltage</th>
<th>freq.</th>
<th>PW</th>
<th>Left settings</th>
<th>voltage</th>
<th>freq.</th>
<th>PW</th>
<th>Behavioral changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 0</td>
<td>AM</td>
<td>1–C+</td>
<td>4.8</td>
<td>135</td>
<td>210</td>
<td>1–C+</td>
<td>4.8</td>
<td>135</td>
<td>210</td>
<td>excessively friendly (hugging), pressured speech</td>
</tr>
<tr>
<td>Day 0</td>
<td>PM</td>
<td>1–C+</td>
<td>3.0</td>
<td>135</td>
<td>210</td>
<td>1–C+</td>
<td>3.0</td>
<td>135</td>
<td>210</td>
<td>OCD symptoms reportedly worse, continuous, insomnia second to task-directed behavior</td>
</tr>
<tr>
<td>Day 1</td>
<td>AM</td>
<td>0–1–C+</td>
<td>2.5</td>
<td>135</td>
<td>210</td>
<td>0–1–C+</td>
<td>2.5</td>
<td>135</td>
<td>210</td>
<td>somewhat sleepy; mania resolved; OCD symptoms persist; admitted to inpatient psychiatry</td>
</tr>
<tr>
<td>Day 2</td>
<td>AM</td>
<td>0–C+</td>
<td>3.0</td>
<td>135</td>
<td>210</td>
<td>0–C+</td>
<td>3.0</td>
<td>135</td>
<td>210</td>
<td>sleepy, but appropriate when aroused</td>
</tr>
<tr>
<td>Day 3</td>
<td>AM</td>
<td>1–0+</td>
<td>2.5</td>
<td>135</td>
<td>90</td>
<td>1–0+</td>
<td>2.5</td>
<td>135</td>
<td>90</td>
<td>OCD symptoms improved</td>
</tr>
<tr>
<td>Day 6</td>
<td>AM</td>
<td>1–0+</td>
<td>3.0</td>
<td>135</td>
<td>90</td>
<td>1–0+</td>
<td>3.0</td>
<td>135</td>
<td>90</td>
<td>troubled by rituals to relieve effects of ‘negative appearance’ of others</td>
</tr>
<tr>
<td>Day 7</td>
<td>AM</td>
<td>1–0+</td>
<td>3.3</td>
<td>135</td>
<td>90</td>
<td>1–0+</td>
<td>3.3</td>
<td>135</td>
<td>90</td>
<td>OCD symptoms improved, now waxing and waning; child-like affect</td>
</tr>
<tr>
<td>Day 8</td>
<td>AM</td>
<td>1–0+</td>
<td>3.5</td>
<td>135</td>
<td>90</td>
<td>1–0+</td>
<td>3.5</td>
<td>135</td>
<td>90</td>
<td>OCD symptoms remain improved; discharged to care of aunt</td>
</tr>
</tbody>
</table>

Statements in quotes are from the patient’s diary, which was submitted by her and entered into the medical record. Medication changes included reduction in her fluoxetine dosage and discontinuation of topiramate on day 0, and the addition of quetiapine (100 mg q.h.s. from day 3) and clonazepam (2 mg b.i.d. from day 3). PW = Pulse width.

**Fig. 2.** A painting made following initial ALIC-NA DBS activation. It was produced after a night-long effort and was described as a ‘surprise’ for the staff. The religious tone is typical of the patient.
Since the symptoms in question were psychiatric and we could not discern any laterality (e.g. such as might be seen with motor symptoms like tremor or stiffness in 1 arm), all programming changes were performed on both devices. Because in previous patients we had noted side effects with stimulation at more ventral contacts and with more intense (higher voltage) stimulation, we decreased the stimulation voltage by 45% (from 4.8 to 3 V) while maintaining the pulse width (210), frequency (135 Hz) and monopolar configuration (i.e. 1–C+).

Following this initial adjustment, the patient spent most of the night awake, alternating between cleaning the adjoining room and painting (fig. 2). Her painting and speech were notable for their hyperreligious content. She also reported that her OCD symptoms were more troublesome than in her preoperative state. She developed bruises on her shins and thighs from obsessively rubbing her legs and reported an increase in her counting behaviors. Her fluoxetine dose was decreased to be sure that it was not exacerbating the mania and her topiramate was discontinued. Treatments with nightly doses of 100 mg of quetiapine and 2 mg of clonazepam were concurrently initiated. No further medication changes were made after day 0.

Since the symptoms in question were psychiatric and we could not discern any laterality (e.g. such as might be seen with motor symptoms like tremor or stiffness in 1 arm), all programming changes were performed on both devices. Because in previous patients we had noted side effects with stimulation at more ventral contacts and with more intense (higher voltage) stimulation, we decreased the stimulation voltage by 45% (from 4.8 to 3 V) while maintaining the pulse width (210), frequency (135 Hz) and monopolar configuration (i.e. 1–C+).

Discussion

Transient mania has been reported following successful DBS implantations in several basal ganglion targets. These have included the globus pallidus internus [19], the STN [17–18, 21–22], the substantia nigra [23] and now the ALIC-NA region [10]. In our patient, the treatment plan involved both a reduction in stimulation field density (via a change in active contact and a change to a bipolar setting which has a smaller and focused stimulation field) and multiple medication changes. The ultimate outcome was positive – her mania resolved and her OCD responded to DBS parameter changes. Multiple modalities were employed to stabilize her clinical course and it is difficult to ascertain the weighted relevance of each. We suspect, based on the time course of improvement, that stimulation played the largest role.

Stimulation-induced mania may result from spread of the stimulation field from the motor regions of gray matter structures into limbic or frontal territories, as has been observed commonly in STN DBS for Parkinson’s disease [24–25]. The ALIC-NA is more richly connected to limbic and frontal regions [26] than the STN or other basal ganglion targets and (based on limited experience) has a correspondingly higher incidence of postoperative psychiatric side effects [10, 12]. The occurrence of transient hypomania with ALIC-NA DBS has been estimated to be as high as 50–67% [10, 12], as contrasted with 4–8% in STN DBS patients [27]. Ventral and anterior stimulation in the ALIC-NA region may produce psychiatric side effects more frequently [10, 12]. It should be noted
that the NA has been implicated in the processing of both executive function and reward-seeking behavior [28–30] mediated via striatal-orbitofrontal circuits. Manic behavior consists in part of impairment in these domains, with patients displaying exaggerated reward-seeking behaviors and overoptimistically assessing the outcomes of their actions. It is unclear what relative roles the NA, striatum and orbitofrontal cortex (OFC) might play in mania: stimulation at the NA has been observed to produce euphoria [31], the striatum has been tied to the experience of pleasure [29] and fMRI data suggest that OFC abnormalities can be present in patients with mania during expected-gain tasks [32]. There is some evidence that ALIC-NA DBS modulates these circuits: high-frequency stimulation of the NA has been shown to inhibit the firing of OFC neurons in rats [33] and intraoperative ventral ALIC-NA stimulation has been found to acutely elevate mood [31]. We hypothesize that the effects we observed occurred either due to stimulation-related impairment of NA-OFC connections or due to activation of related areas in the ALIC-NA itself, but these relationships will require considerable and detailed study to elucidate.

Though the degree of stimulation spread is partially dictated by lead placement – which sets the center of the stimulation field – the shape and intensity of the electrical field also play a role in determining potential side effects/benefits. One reason for mania in our case may have been the high initial stimulation intensity. Aggregate stimulation intensity can be approximated by utilizing the composite measure referred to as total energy delivered (TED) [34]. When examining TED over time (fig. 3), calculations revealed maximal intensity at activation (TED = 1,098.27) with a reduction over the time course of OCD improvement (TED = 188.67 at discharge and TED = 194.98 one year postoperatively). It should be noted that even minor variation in lead activations or configurations can result in large changes in the region influenced by the stimulation field [35]. We employed a Medtronics 3387-IES lead and a shift from the 0 (or ventral) contact to contact 1 corresponded to a shift of 4 mm. Differences of as little as 1 mm have been implicated in substantial changes in field distribution [36]. In this patient we observed an improvement in mania following a decrease in stimulation intensity and a subjective improvement in OCD symptomatology when we switched to a bipolar stimulation montage (but still employing ventral contacts). It is difficult to separate the effects of TED from those of electrode position and stimulation montage, and the time-response of these symptoms is unknown.

It is possible that patients with a predisposition to psychiatric side effects have a lower intraoperative threshold for stimulation-induced behavioral manifestations. Some of our OCD patients displayed smiles, panic or laughter during intraoperative test stimulation (though this occurred less frequently during subsequent programming [16]). Stimulation-induced smiles occurred during intraoperative test stimulation of 5 of 6 members of our initial OCD DBS cohort [12, 31, 37]. These episodes were easily induced (i.e. seen at low voltages) and were usually short in duration. It is unknown whether OCD patients are predisposed to these manifestations or whether these behaviors may also be observed in different cohorts of patients when utilizing the same brain targets.

Though lesion effects might be invoked to explain postoperative side effects, they are unlikely to be implicated in our case. The pulse generators (batteries) were not activated until 30 days following surgery, and the patient was not manic during this time. In most cases lesion effects would be expected to appear immediately. This was not the case for our patient. Her mania appeared immediately following activation of her stimulators. The contribution of the medication changes made is more difficult to assess. Although medication effects cannot be discounted as underpinning at least part of her symptomatic improvement, it should be noted that our patient’s mood and OCD symptom changes tracked with our programming adjustments (they occurred temporally within hours of the programming changes). It should also be noted that no medication changes were made after day 0 of symptoms.

DBS programming for psychiatric disease can be complex and difficult to manage. Our patient’s case illustrates the potential perils of stimulation-induced side effects as well as the importance of an aggressive management approach. Management may include programming changes, medication changes and even hospitalization. Hardware malfunction should routinely be ruled out as a potential cause. In cases in which a loss of benefit is observed, lead migration should be considered as a possibility and lead localization via neuroimaging may be required.

Potential treatment approaches to stimulation-induced side effects include a reduction in stimulation intensity (current density and voltage) or a shift in point of stimulation to more dorsal contacts on the electrode. Patients should be monitored for impulsivity and suicidal tendencies as psychiatric side effects have the potential to blossom quickly into severe adverse events.
Patients should not, at this time, be treated with DBS. A multidisciplinary team is capable of managing OCD in this patient. Our practice in treating OCD patients has shifted away from the choice of high initial stimulation strengths and towards more gradual increases in voltage. By doing so, we hope to avoid stimulation-induced manic responses of the sort that were seen in this patient.

**References**


